Back to Goldman Sachs Group Inc. Goldman Sachs Group Inc.

RNAC

Showing 6 of 7 quarters

Position history for Goldman Sachs Group Inc.Goldman Sachs Group Inc.'s holdings in Cartesian Therapeutics, Inc.

Yes. Goldman Sachs holds 51,529 shares of RNAC (Cartesian Therapeutics), worth $371,524, as of its Q3 2026 13F filing. It reduced the position by 29,043 shares (-36.0%) from Q2 2026. Goldman Sachs has held RNAC since Q1 2026, across 3 quarterly 13F filings.

Current Value

$371,524

Current Shares

51,529

Total Value Change

-$121,449

Total Shares Change

—

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q3
Latest
Decreased
51,529
-36.0%
$371,5240.0%$7.21
0
2026-Q2
Increased
80,572
+160.5%
$839,5600.0%$10.42
40
2026-Q1
New
30,927
-
$190,2010.0%$6.15
35
2025-Q2
Exited
0
-100.0%
$00.0%$10.39
0
2025-Q1
Decreased
15,775
-42.7%
$207,9150.0%$13.18
0
2024-Q4
Increased
27,525
+142.8%
$492,9730.0%$17.91
39

Other major holders of RNAC: FMR LLC, Squarepoint Ops LLC

Optional analytics helps us improve. How it’s used